Biological therapy in genital psoriasis in women.
biologic therapy
genital
psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
26
07
2019
revised:
07
09
2019
accepted:
04
10
2019
pubmed:
9
10
2019
medline:
20
11
2020
entrez:
10
10
2019
Statut:
ppublish
Résumé
Genital psoriasis (GenPs) is a frequent manifestation of psoriasis, causing distress, especially in women. We prospectively studied a population of 74 psoriatic women with severe and generalized psoriasis eligible to biologic therapy, to examine which biologic therapy is more effective on GenPs and to study possible associations between PASI severity and GenPs. Overall, 25/74 (34%) had GenPs: 6 received Ixekizumab, 7 Ustekinumab, 8 Adalimumab, 2 Secukinumab, 1 Etanercept, 1 Certolizumab. Therapies were administered based on PASI severity, independently from the presence of GenPs. Side effects, PASI score, sPGA-G scale for GenPs were recorded at time 0 and after 6 month of therapy. The mean sPGA-G scale value was 2.8 before treatment. After biologic therapy, all patients except one, improved of at least one point. Mostly, patients treated with anti-IL17 (Secukinumab, Ixekizumab) and anti-IL12/23 (Ustekinumab) improved. Mean PASI ranged from 10 to 16.3 before treatment. After 6 months of therapy, 4 anti-TNFα patients, 6 anti-IL17 and 1 anti-IL12/23, reached PASI 90. At time 0, no correlation between PASI and sPGA-G was visible (Pearson r = 0.10, p = .620). From our data, GenPs apparently responds favorably to IL17A inhibitors, but further studies, based on larger numbers of patients, are needed.
Substances chimiques
Biological Products
0
Dermatologic Agents
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13110Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Cozzani, E. (2010). The quality of life in Italian psoriatic patients treated with biological drugs. Giornale Italiano di Dermatologia e Venereologia, 145, 709-712.
Duarte, G. V. (2018). Psoriasis and sexual dysfunction: Links, risks, and management challenges. Psoriasis, 8, 93-99.
Kaushik, S. B. (2019). Review of safety and efficacy of approved systemic psoriasis therapies. International Journal of Dermatology, 58, 649-658.
Kellen, R. (2016). Efficacy and safety of ustekinumab in adolescents. Pediatric Health, Medicine and Therapeutics, 19, 109-120.
Meeuwis, K. A. (2011). Genital psoriasis: A systematic literature review on this hidden skin disease. Acta Dermato-Venereologica, 91, 5-11.
Meeuwis, K. A. (2015). Genital psoriasis awareness program: Physical and psychological care for patients with genital psoriasis. Acta Dermato-Venereologica, 95, 211-216.
Merola, J. F. (2017). The static Physician's global assessment of genitalia: A clinical outcome measure for the severity of genital psoriasis. Journal of Drugs in Dermatology, 16, 793-799.
Pham, P. A. (2019). Time until onset of action when treating psoriatic arthritis: Meta-analysis and novel approach of generating confidence intervals. Rheumatology International, 39, 605-618.
Ryan, C. (2018). IXORA-Q study group. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. The British Journal of Dermatology, 179, 844-852.
Wu, S. (2016). Hormonal factors and risk of psoriasis in women: A cohort study. Acta Dermato-Venereologica, 96, 927-931.
Yosipovitch, G. (2018). Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study. The Journal of Sexual Medicine, 15, 1645-1652.